Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

Multiple medications are now available to treat IgA nephropathy, including budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). But Miller’s treatment options were more limited ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

IgA nephropathy is a kidney disease ... So far, this includes Tarpeyo (budesonide), a corticosteroid, and Filspari (sparsentan), a type of medication known as an endothelin and angiotensin ...

The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan ... as a foundational therapy in IgA nephropathy (IgAN).

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

IgA nephropathy is the leading cause of kidney failure. Around half of those with IgA nephropathy will see worsening kidney function over many years. For some people, this happens more quickly.

IgA nephropathy (IgAN), also called Berger's ... Concomitant use with a strong CYP3A inhibitor increases sparsentan exposure which may increase the risk of FILSPARI adverse reactions.